Are Anti-rhGAA Antibodies a Determinant of Treatment Outcome in Adults with Late-Onset Pompe Disease? A Systematic Review

• Published in: Biomolecules (Basel, Switzerland) Vol. 13; no. 9; p. 1414
• Main Authors: Ditters, Imke A. M., van Kooten, Harmke A., van der Beek, Nadine A. M. E., van der Ploeg, Ans T., Huidekoper, Hidde H., van den Hout, Johanna M. P.
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.09.2023; MDPI
• Subjects: Adult; Adults; Age; alpha-Glucosidases - therapeutic use; anti-rhGAA antibodies; Antibodies; Care and treatment; Case reports; Clinical trials; Cohort analysis; Enzyme Replacement Therapy; Enzymes; Glycogen Storage Disease Type II - drug therapy; Glycogenosis; Health aspects; Humans; Immunoglobulin G; late-onset Pompe disease; Lysosomal storage diseases; Medical research; Muscle strength; Patient outcomes; Patients; Review; Skeletal muscle; Systematic review; Treatment Outcome; Viral antibodies; Netherlands; anti-rhGAA antibodies; enzyme replacement therapy; late-onset Pompe disease; systematic review
• ISSN: 2218-273X; 2218-273X
• DOI: 10.3390/biom13091414

Background: Pompe disease is a lysosomal storage disease characterised by skeletal and respiratory muscle weakness. Since 2006, enzyme replacement therapy (ERT) with alglucosidase alfa has been available. ERT significantly improves the prognosis of patients with Pompe disease. The effect of high antibody titres on treatment response in adults with late-onset Pompe disease (LOPD) remains unclear but may contribute to interpatient variation. We therefore conducted a systematic review on this subject. Methods: A systematic search was performed in Embase, Medline Ovid, Web of Science, Psych Info Ovid, Cochrane (Clinical Trials only), and Google Scholar (random top-200). Articles were included if they involved adults with LOPD treated with alglucosidase alfa and mentioned anti-rhGAA antibodies or antibody titres. In addition, articles mentioning dosages different from the standard recommended dosage were included. Results: Our literature search retrieved 2562 publications, and 17 fulfilled our selection criteria, describing 443 cases. Seven publications reported on anti-rhGAA antibody titres on a group level, with the percentage of patients with a high titre as defined in the included articles ranging from 0–33%. Six publications reported on the effect of anti-rhGAA antibody titre on clinical course, and four found no correlation. Two studies reported a negative effect on treatment. The first study found a greater improvement in Medical Research Council (MRC) score in patients with no detectable antibody titre. In the second study, a patient discontinued ERT due to a declining neuromuscular state as a result of high anti-rhGAA antibody titres. Seven publications reported on 17 individual patients with a high antibody titre (range 1:12,800–1:3,906,250). In only two cases were high-sustained neutralising antibodies reported to interfere with treatment efficacy. Conclusions: No clear effect of anti-rhGAA IgG antibodies on treatment response could be established for the majority of LOPD patients with a high antibody titre. In a minority of patients, a clinical decline related to (possible) interference of anti-rhGAA antibodies was described.